Liraglutide
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
At a glance
- Best for
- Adults with type 2 diabetes and/or obesity (Saxenda also approved for adolescents 12+ with obesity) under a prescriber
- Typical dose
- Diabetes: titrated to 1.2-1.8 mg once daily; weight management: titrated to 3.0 mg once daily
- Time to effect
- Glucose lowering within weeks; weight loss over months
- Main caution
- Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist that boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. It is given by daily subcutaneous injection. It is FDA-approved for type 2 diabetes (Victoza), for chronic weight management (Saxenda), and to reduce cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Is it worth it for you?
Worth considering if…
- You have type 2 diabetes needing better glycemic control, prescribed and titrated by a clinician
- You have obesity (BMI >=30) or overweight (BMI >=27) with a weight-related comorbidity, using it with diet and activity
- You have type 2 diabetes with established cardiovascular disease where proven event reduction is wanted
Probably skip if…
- You have a personal or family history of medullary thyroid carcinoma or MEN 2
- You have a history of pancreatitis or cannot tolerate daily injections and GI titration
- You are pregnant or seeking rapid cosmetic weight loss without medical oversight
Evidence at a glance
| Goal | Evidence | Effect | Best fit | Time |
|---|---|---|---|---|
| type 2 diabetes glycemic control | Strong Evidence | HbA1c reduction of roughly 1.0-1.5% versus placebo or active comparators | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
| chronic weight management in obesity | Strong Evidence | About 8% mean body-weight reduction versus ~2.6% with placebo at 56 weeks (SCALE) | Adults with obesity or overweight with a weight-related condition | Months |
| cardiovascular event reduction in type 2 diabetes | Strong Evidence | About 13% relative reduction in major adverse cardiovascular events versus placebo (LEADER) | Adults with type 2 diabetes and high cardiovascular risk or established disease | Months to years |
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 LEAD program randomized adults with type 2 diabetes and showed liraglutide reduced HbA1c by about 1.0-1.5% with weight loss and low intrinsic hypoglycemia risk, performing favorably against comparators including glimepiride and insulin glargine on combined glycemic and weight endpoints. These trials supported approval for type 2 diabetes as Victoza.
Bottom line: Liraglutide reliably lowers HbA1c with modest weight loss in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 SCALE Obesity and Prediabetes trial, adults without diabetes who received liraglutide 3.0 mg daily with lifestyle intervention lost about 8% of body weight versus roughly 2.6% with placebo over 56 weeks, with more participants achieving 5% and 10% loss. A separate SCALE trial supported benefit in type 2 diabetes. Weight is regained after discontinuation, consistent with chronic-disease treatment.
Bottom line: At the 3.0 mg dose, liraglutide produces moderate, clinically meaningful weight loss while treatment continues.
cardiovascular event reduction in type 2 diabetes
Disease adjunctThe LEADER trial randomized adults with type 2 diabetes at high cardiovascular risk to liraglutide or placebo and found about a 13% relative reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with a significant reduction in cardiovascular and all-cause death. This outcome trial underpins the cardiovascular risk-reduction indication for Victoza.
Bottom line: Liraglutide reduces major cardiovascular events and cardiovascular death in higher-risk type 2 diabetes.
How to take it
- Typical dose
- Prescriber-titrated: diabetes started at 0.6 mg daily and increased to 1.2-1.8 mg; weight management increased weekly to 3.0 mg daily
- Timing
- Once daily, any time, with or without meals; same time each day preferred
- With food
- Independent of food; subcutaneous injection in abdomen, thigh, or upper arm
- How long to try
- Chronic therapy; weight tends to return after stopping, so the prescriber plans long-term use and reassessment
What to track
- HbA1c and fasting glucose (in diabetes)
- Body weight
- Signs of pancreatitis (severe persistent abdominal pain)
- Heart rate
- Gallbladder symptoms and renal function during GI illness
Safety
Common side effects
Nausea, vomiting, diarrhea, constipation (dose-related, usually transient), Abdominal pain and dyspepsia, Decreased appetite, Injection-site reactions, Headache
Serious risks
- Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents (human relevance unknown)
- Acute pancreatitis
- Gallbladder disease (cholelithiasis, cholecystitis)
- Acute kidney injury from dehydration with severe GI symptoms
- Severe hypoglycemia when combined with insulin or sulfonylureas
- Increased heart rate
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to liraglutide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue when pregnancy is recognized as weight loss offers no benefit and safety is not established.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
Choosing a product
Look for
- Only obtain via a licensed prescriber and pharmacy as FDA-approved Victoza or Saxenda
- Supplied as a prefilled multidose pen with verified dose
- Dispensed with titration schedule and counseling on GI effects and injection technique
Be skeptical of
- Compounded or grey-market 'liraglutide' with unverified purity
- Research-only powders sold to be reconstituted for injection
- Any source marketing it for rapid weight loss without medical evaluation or titration
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
cardiovascular event reduction in type 2 diabetes
- Marso et al., 2016 — PMC (2016) link
Track Liraglutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.